It is known that Lorviqua, a third-generation ALK-inhibiting non-small cell lung cancer treatment, is on the verge of insurance benefits through drug price negotiations. As a result, new treatment options are expected to be created for patients who have not seen any effect even if they use first and second-generation treatments.

The drug was recognized for its benefit adequacy by the NHIS in April, which recently disclosed the progress of drug price negotiations on the drug. According to the industry on the 10th, the NHIS recently announced on its website that the NHIS is negotiating prices of Lorviqua 25mg, Lorviqua100mg and Dopa check.

The two drugs passed the HIRA on April 7. Pfizer's